Fewer than a tenth of patients that would benefit from obesity jabs including Wegovy have access to them, states the WHO as it issues its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major barriers to universal availability to the treatments that can aid individuals in losing considerable body mass, notes the body.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic scenario, the production of these medications could only cover about 100 million people – fewer than 10% of those who need them, according to the WHO.
The guideline urges countries and companies to widen availability, via measures such as voluntary licensing.
The intellectual property rights on the active ingredient – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Injections Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, reduce hunger and increase the sense of being full so individuals reduce food intake.
Individuals usually see weight reduction within a few weeks of starting on the once-weekly jabs.
Studies indicates users may regain a significant portion within a year of discontinuing the drug, when their normal hunger resume.
To be above a healthy weight elevates your chance for developing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
